The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication. The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose mea

Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion. Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.

Discover how the Basel Area and Roche are institutionalizing longevity as an asset class through a CHF 1.4B pivot into predictive, human-centric infrastructure.

Executive Summary The Event: Global venture capital firm QAI Ventures launches Singapore’s inaugural Quantum Accelerator in partnership with Enterprise Singapore, deploying an initial SGD 300,000 capital package per deep-tech venture. The Thesis: Quantum computing represents the definitive backend infrastructure for the luxury longevity economy. The transition from basic discovery to biological engineering requires processing capacities capable of bypassing legacy lab

Executive Summary The Event: ŌURA acquires Galen AI, a Y Combinator-backed startup specializing in AI-powered aggregation of medical records, lab results, medications, and wearable data into a unified interface. The Thesis: The longevity economy is shifting from wearable devices to integrated Health Intelligence Platforms — where AI, biometrics, and longitudinal clinical data converge into a continuous operating system for preventive health.

QAI Ventures, SoftBank, and HorizonX anchor a specialized Quantum-AI hub in Singapore. Quantum computing is moving from theoretical lab work to the industrialization of the longevity asset class. Early adopters of "Computational Longevity" will mitigate the biological and financial risks of aging through predictive simulation.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.